Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway

Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases with limited treatment options. Moreover, its prevalence is doubled in type 2 diabetes mellitus (T2DM). Kaempferol (KAP) is a flavonoid compound that has been suggested to have beneficial effects on NAFLD, but studies...

Full description

Bibliographic Details
Main Authors: Na Li, Lin Yin, Jiamin Shang, Meidai Liang, Zhaoyu Liu, Haiguang Yang, Guifen Qiang, Guanhua Du, Xiuying Yang
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Kaempferol
NAFLD
Lipid accumulation
Sirt1
AMPK
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223009046

Similar Items

Similar Items